Seurat Therapeutics, a US-based drug developer that emerged out of University of Chicago (UChicago), raised $750,000 in a seed round today backed by the institution’s Polsky Innovation Fund, according to Chicago Inno.
The round also featured Scott Meadow, professor of entrepreneurship at UChicago’s Booth School of Business, and unnamed employees of Seurat.
Founded in 2016, Seurat Therapeutics is developing a nasal spray to prevent and treat migraines. The funding will enable the spinout to launch human clinical trials.
Seurat was co-founded by Martin Sanders, founding member of the Polsky Innovation Fund’s advisory board, Yuan Zhang, an associate in the same fund, and Richard Kraig, professor in the Department of Neurology and William Mabie professor in neurosciences. Kraig also leads the Migraine Headache clinic at UChicago.
Kraig said: “We are working on a simple solution to a very complex problem. We think this treatment can prevent migraines in the millions of frequent and chronic migraine sufferers, and be the first treatment to address the underlying cause of migraines, rather than just the symptoms of severe pain and life-altering disability.”
